1. Clinical Overview
Solifenacin succinate is a competitive, specific muscarinic acetylcholine receptor antagonist used for the treatment of overactive bladder (OAB) syndrome with symptoms of urge urinary incontinence, urgency, and urinary frequency. It exhibits functional selectivity for the bladder over salivary glands, offering a favorable tolerability profile.
| Onset | Duration | Bioavailability |
|---|---|---|
| Clinical improvement in symptoms may be observed within 1-2 weeks of starting therapy, with maximal therapeutic effect typically achieved by 4-12 weeks. | Approximately 24 hours, supporting once-daily dosing. | Approximately 90%. |
2. Mechanism of Action
Solifenacin is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3, M4, M5), with the highest functional selectivity for the M3 receptor subtype. In the bladder, M3 receptors are primarily responsible for detrusor muscle contraction. By blocking these receptors, solifenacin reduces involuntary detrusor contractions, increases bladder capacity, and decreases the frequency of micturition.
3. Indications & Uses
- Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence
- Treatment of overactive bladder with symptoms of urgency
- Treatment of overactive bladder with symptoms of urinary frequency
4. Dosage & Administration
Adult Dosage: 5 mg once daily. May be increased to 10 mg once daily if the 5 mg dose is well tolerated but requires greater efficacy.
Administration: Swallow the tablet whole with a glass of water, with or without food. Do not crush, chew, or split. Should be taken at approximately the same time each day.
5. Side Effects
Common side effects may include:
- Dry mouth (11-27%)
- Constipation (5-13%)
- Blurred vision (3-5%)
- Dyspepsia
- Nausea
- Dry eyes
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Ketoconazole, Itraconazole, Voriconazole, Posaconazole | Potent CYP3A4 inhibitors increase solifenacin plasma levels. Risk of toxicity. | Major |
| Clarithromycin, Telithromycin, Erythromycin | Moderate CYP3A4 inhibitors may increase solifenacin exposure. | Moderate |
| Rifampicin, Carbamazepine, Phenytoin, St. John's Wort | Potent CYP3A4 inducers decrease solifenacin plasma levels, reducing efficacy. | Moderate |
| Other anticholinergics (e.g., oxybutynin, tolterodine, tricyclic antidepressants, first-gen antihistamines) | Additive anticholinergic side effects (dry mouth, constipation, blurred vision, cognitive effects). | Moderate |
| Drugs prolonging QT interval (e.g., Class Ia/III antiarrhythmics, macrolides, some antipsychotics) | Potential additive effect on QT prolongation, increasing arrhythmia risk. | Moderate |
| Metformin | Solifenacin may slightly decrease metformin absorption; monitor glycemic control. | Minor |
| Digoxin | Solifenacin may increase digoxin levels (P-gp inhibition); monitor digoxin levels. | Moderate |
7. Patient Counselling
- DO take the tablet whole with water, with or without food.
- DO take it at the same time each day to help you remember.
- DO inform your doctor about all other medicines, including herbal remedies.
- DO maintain adequate fluid intake unless advised otherwise by your doctor.
- DO report any signs of infection, eye pain, or difficulty urinating immediately.
- DONT crush, chew, or break the tablet.
- DONT consume grapefruit or grapefruit juice while on this medication.
- DONT double the dose if you miss one. Skip it and take the next dose at the regular time.
- DONT stop the medication abruptly without consulting your doctor.
8. Toxicology & Storage
Overdose: Exaggerated anticholinergic effects: severe dry mouth, severe constipation, urinary retention, blurred vision, tachycardia, drowsiness progressing to stupor/coma, delirium, hallucinations, convulsions, respiratory depression, and cardiac arrhythmias (QT prolongation).
Storage: Store below 30°C. Protect from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.